Skip to content
The Nexus
DossierENTITY

BigHat Biosciences

Coverage of BigHat Biosciences in the Nexus archive.

Earliest in view: May 26 · 08:30 UTCMost recent: May 26 · 08:30 UTC
Co-mentioned in this coverage
Peyton Greensideperson1Johnson & Johnsonorganization1Merckorganization1Amgenorganization1Abbvieorganization1Lillyorganization1AI drug developmenttopic1
Recent coverage
  • HEALTHMay 26 · 08:30 UTCSTAT NEWS
    STAT+: An AI biotech CEO sets the record straight on AI drug development hype

    Peyton Greenside, CEO of BigHat Biosciences, critiques the hype around AI-driven drug development, emphasizing that while AI can rapidly design proteins, the actual drug-making process remains time-consuming and costly. The company, founded in 2019, partners with major pharmaceutical firms like Johnson & Johnson, Merck, and Amgen.